Supernus Pharmaceuticals of Rockville received final approval from the U.S. Food and Drug Administration, effective Aug. 16, for Trokendi XR, a once-daily extended release formulation of topiramate for the treatment of epilepsy. The company expects to launch the product and for it to be available in pharmacies over the next few weeks.
The company reported that revenue for the second quarter was $281,000, up from $91,000 a year earlier. Its net loss widened to $27.4 million from a loss of $10 million a year earlier. Selling, general and administrative expenses almost tripled to $12.2 million due to increased sales and marketing costs related to the commercial launch of Oxtellar XR and the planned launch of Trokendi XR.
Rockville biotechnology company MacroGenics has met a milestone with its first patient dosed in a Phase 1 trial of a treatment for cancer tumors called MGA271, triggering a $10 million payment to the company from partner Les Laboratoires Servier.
MacroGenics plans to enroll 45 patients within three cohort groups and expects to complete the Phase 1 trial in 2014. MGA271 has significant potential to treat a variety of solid tumors, said Scott Koenig, president and CEO of MacroGenics, in a statement.
Famous Daves of America is closing a restaurant on Quince Orchard Road in Gaithersburg on Sept. 8 and opening a new restaurant Sept. 16 at 20660 Seneca Meadows Parkway, Germantown.
The relocation to Germantown is based on strategic decisions that support the companys future growth, said John Spoon, director of operations for Famous Daves. The 5,200-square-foot restaurant will seat 171 people inside and accommodate another 57 patrons on a 1,600-square-foot patio.
There also is a Famous Daves restaurant in Frederick, among other cities in Maryland.
Originally posted here:
Earnings & Deals -- Gazette.Net